Effects of Intravenous Nifekalant, A Class III Antiarrhythmic Drug, on Atrial Vulnerability Parameters in Patients with Paroxysmal Atrial Fibrillation

PACE - Pacing and Clinical Electrophysiology

Volumn 27, Issue 2, 2004, Pages 212-217

  Minami, Takako ^a   Isomoto, Shojiro ^a   Nakao, Kojiro ^a   Komiya, Norihiro ^a   Fukae, Satoki ^a   Centurion, Osmar Antonio ^a,b   Yano, Katsusuke ^a  

^a NAGASAKI UNIVERSITY   (Japan)

^b Dept Hemodynamics Electrophysiology ^*  (Paraguay)

Author keywords

Atrial fibrillation; Atrial refractoriness; Class III antiarrhythmic drug; Conduction time; Nifekalant

Indexed keywords

ANTIARRHYTHMIC AGENT; NIFEKALANT;

ADULT; AGED; ARTICLE; CALCULATION; CARDIOVASCULAR PARAMETERS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART ATRIUM; HEART ATRIUM CONDUCTION; HEART ATRIUM FIBRILLATION; HEART ELECTROPHYSIOLOGY; HEART FUNCTION TEST; HUMAN; MALE; QUANTITATIVE ANALYSIS; REFRACTORY PERIOD;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL APPENDAGE; ATRIAL FIBRILLATION; ATRIAL FUNCTION; BUNDLE OF HIS; CORONARY VESSELS; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FEMALE; HEART VENTRICLES; HUMANS; INFUSIONS, INTRAVENOUS; LINEAR MODELS; MALE; MATCHED-PAIR ANALYSIS; MIDDLE AGED; PYRIMIDINONES; REFRACTORY PERIOD, ELECTROPHYSIOLOGICAL; TIME FACTORS;

EID: 1342301458     PISSN: 01478389     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8159.2004.00412.x     Document Type: Article

References (32)

1. Nakaya H, Tohse N, Takeda Y, et al. Effects of MS-551, a new class III antiarrhythmic drug, on action potential and membrane currents in rabbit ventricular myocytes. Br J Pharmacol 1993; 109:157-163.
2. Sato R, Koumi S, Hisatome I, et al. A new class III antiarrhythmic drug, MS-551, blocks the inward rectifier potassium channel in isolated guinea pig ventricular myocytes. J Pharmacol Exp Ther 1995; 274:469-474.
3. + current in rabbit ventricular myocytes. Cardiovasc Res 1996; 31;963-974.
4. Martin DK, Nakaya Y, Wyse KR, et al. Inhibition of ATP-sensitive potassium channels in cardiac myocytes by the novel class III antiarrhythmic agent MS-551. Pharmacol Toxicol 1995; 77:65-70.
5. Kamiya J, Ishii M, Katakami T. Antiarrhythmic effects of MS-551, a new class III antiarrhythmic agent, on canine models of ventricular arrhythmia. Jpn J Pharmacol 1992; 58:107-115.
6. Kondoh K, Hashimoto H, Nishiyama H, et al. Effects of MS-551, a new class III antiarrhythmic drug, on programmed stimulation-induced ventricular arrhythmias, electrophysiology, and hemodynamics in a canine myocardial infarction model. J Cardiovasc Pharmacol 1994; 23:674-680.
7. Friedrichs GS, Chi L, Gralinski MR, et al. MS-551 protects against ventricular fibrillation in a chronic canine model of sudden cardiac death. J Cardiovasc Pharmacol 1995; 25:314-323.
8. Takenaka K, Yasuda S, Miyazaki S, et al. Initial experience with nifekalant hydrochloride (MS-551), a novel class ni antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Jpn Circ J 2001; 65:60-62.
9. Yamada A, Motomura S, Hashimoto K. Comparison of direct negative chronotropic and positive inotropic effects of sematilide to those of E-4031 and MS-551 and the reverse frequency-dependent prolongation of cardiac refractoriness of sematilide. J Cardiovasc Pharmacol 1996; 27:159-66.
10. Hashimoto K, Haruno A, Hirasawa A, et al. Effects of the new class III antiarrhythmic drug MS-551 and d-sotalol on canine coronary ligation- reperfusion ventricular arrhythmias. Jpn J Pharmacol 1995; 68:1-9.
11. Chen J, Komori S, Li B, et al. IK independent class III actions of MS-551 compared with sematilide and dofetilide during reperfusion in anaesthetized rats. Br J Pharmacol 1996; 119:937-942.
12. Isomoto S, Konoe A, Centurion OA, et al. Electrophysiological effects of MS-551 in humans: A class III antiarrhythmic agent. PACE 1995; 18:2022-2027.
13. Shiga T, Matsuda N, Fuda Y, et al. Antiarrhythmic effect of nifekalant on atrial tachyarrhythmia in four patients with severe heart failure. J Cardiol 2002; 39:159-164.
14. Wyndham CRC, Amat-y-Leon F, Wu D, et al. Effects of cycle length on atrial vulnerability. Circulation 1977; 55:260-267.
15. Ohe T, Matsuhisa M, Kamakura S, et al. Relation between the widening of the fragmented atrial activity zone and atrial fibrillation. Am J Cardiol 1983; 53:1219-1222.
16. Buxton AE, Waxman HL, Marchlinski FE, et al. Atrial conduction. Effect of extrastimuli with and without atrial dysrhythmias. Am J Cardiol 1984; 54:755-761.
17. Komiya N, Isomoto S, Nakao K, et al. Electrophysiological abnormalities of the atrial muscle in patients with paroxysmal atrial fibrillation associated with hyperthyroidism. Clin Endocrinol 2002; 56:39-44.
18. Kumagai K, Goudo N, Matsuo K, et al. Wavelength index: A predictor of the response to disopyramide in paroxysmal lone atrial fibrillation. Cardiology 1994; 85:184-192.
19. Shimizu A, Fukatani M, Tanigawa M, et al. Mechanism of the suppression of repetitive atrial firing by isoproterenol-comparison with disopyramide. Int J Cardiol 1994; 43:175-184.
20. Kuhlkamp V, Meerhof J, Schmidt F, et al. Electrophysiologic effects and efficacy of cibenzoline on stimulation-induced atrial fibrillation and flutter and implications for treatment of paroxysmal atrial fibrillation. Am J Cardiol 1990; 65:628-632.
21. Hano O, Konoe A, Hirata T, et al. Effects of aprindine on electrophysiological properties of the atrial muscle in man. Jpn Circ J 1995; 59:337-346.
22. Pop T, Treese N, Kang JC, et al. Effect of intravenous flecainide on atrial vulnerability in man. Klin Wochenschr 1983; 61:609-615.
23. Matsuo K, Kumagai K, Annoura M, et al. Mechanism of antiarrhythmic effects of class Ic drugs in paroxysmal atrial fibrillation in man. Cardiology 1998; 89:119-123.
24. Kostin S, Klein G, Szalay Z, et al. Structural correlate of atrial fibrillation in human patients. Cardiovasc Res 2002; 54:361-379.
25. Bosch RF, Nattel S. Cellular electrophysiology of atrial fibrillation. Cardiovasc Res 2002; 54:259-269.
26. Hordof AJ, Edie R, Malm JR, et al. Electrophysiologic properties and response to pharmacologic agents of fibers from diseased human atria. Circulation 1976; 54:774-779.
27. Naitoh N, Taneda K, Tagawa M, et al. Electrophysiologic effects of intravenous MS-551, a novel class III antiarrhythmic agent, on human atrium and ventricle. Jpn Heart J 1998; 39:297-305.
28. Watanabe H, Watanabe I, Nakai T, et al. Frequency-dependent electrophysiological effects of flecainide, nifekalant and d,1-sotalol on the human atrium. Jpn Circ J 2001; 65:1-6.
29. Burashnikov A, Antzelevitch C. Reinduction of atrial fibrillation immediately after termination of the arrhythmia is mediated by late phase 3 early afterdepolarization-induced triggered activity. Circulation 2003; 107:2355-2360.
30. Hayashi H, Fujiki A, Tani M, et al. Different effects of class Ic and III antiarrhythmic drugs on vagotonic atrial fibrillation in the canine heart. J Cardiovasc Pharmacol 1998; 31:101-107.
31. Rensma PL, Allessie MA, Lammers WJ, et al. Length of excitation wave and susceptibility to reentrant atrial arrhythmias in normal conscious dogs. Circ Res 1988; 62:395-410.
32. Wiener N, Rosenblueth A. The mathematical formation of the problem of conduction of impluses in a network of connected excitable elements, specifically in cardiac muscle. Arch Inst Cardiol Mex 1946; 16:205-265.